CA2220103C - Composition comprising amoxycillin and clavulanic acid - Google Patents
Composition comprising amoxycillin and clavulanic acid Download PDFInfo
- Publication number
- CA2220103C CA2220103C CA002220103A CA2220103A CA2220103C CA 2220103 C CA2220103 C CA 2220103C CA 002220103 A CA002220103 A CA 002220103A CA 2220103 A CA2220103 A CA 2220103A CA 2220103 C CA2220103 C CA 2220103C
- Authority
- CA
- Canada
- Prior art keywords
- amoxycillin
- day
- clavulanic acid
- potassium clavulanate
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Paediatric aqueous liquid suspension formulations comprising amoxycillin trihydrate and potassium clavulanate in a ratio of from 6:1 to 8:1 are provided for use in a BID dosage regimen for treating bacterial infection.
Description
WO 96J34b~05 PCT/EP96J01881 Composition comprising Amoxycillin and Clavulanic acid This invention relates to a method of treating paediatric bacterial infections using a combination of the antibiotic amoxycillin and the beta-lactamase inhibitor potassium clavulanate, to pharmaceutical formulations for use in such method and to methods for the manufacture of such formulations.
The combination of the antibiotic amoxycillin, as amoxycillin trihydratc:, and potassium clavulanate, is a well known and widely used oral medicament for bacterial infections, marketed by SmithKline Beecham in many countries under the trade mark A,ugmentin.
Regulatory approval has been obtained, for instance in the UK and U'S, for W blets containing amoxycillin (250mg) and potassium clavulanate (125mg) (ratio
The combination of the antibiotic amoxycillin, as amoxycillin trihydratc:, and potassium clavulanate, is a well known and widely used oral medicament for bacterial infections, marketed by SmithKline Beecham in many countries under the trade mark A,ugmentin.
Regulatory approval has been obtained, for instance in the UK and U'S, for W blets containing amoxycillin (250mg) and potassium clavulanate (125mg) (ratio
2:1), in a three times daily dosing schedule (tid), so that the daily dose of am.oxycillin and potassium clavulanate is 750mg and 375mg respectively (the weights being expressed as the free parent acids amoxycillin and clavulanic acid, this manner of expression being used throughout). In severe infections, the ratio is changed to 4:1, so that the daily doses of amoxycillin and potassium clavulanate are 1500mg and 375mg respectively. In other countries such as Italy and Spain, tablets containing amoxycillin (875mg) and potassium clavulanate (125mg) (ratio 7:1) are approved for twice daily dosing (bid). In France, sachets comprising amoxycillin ( 1000m.g) and potassium clavulanate ( 125mg) (ratio 8:1 ) are marketed, for reconstitution witt:~ water prior to use, as an individual dosage for adults.
For children, it is preferred to provide the combination as a powder which is reconstituted prior to use as a liquid aqueous suspension. The usual recommended daily dosage is 20/Smg/kg/day (LTK and USA) or 3017.5mg/kg/day (Continental >=;urope) amoxycillin/potassium clavulanate (ratio 4:1), in divided doses every eight hours. For more severe infections such as otitis media, sinusitis and lower mspiraotory tract infections, the recommended dose is 40/lOmg/kg/day (UK and LJSA) or 60/lSmg/kg/day (Continental Europe), in three divided doses. For convenience, the powders are provided in amounts which are made up into a range of volumes of suspension so that a small volume, typically about Sml, contains a unit dosage. In other countries such as Italy, approval has also been given for using the higher strength paediatric formulation on a twice a day (bid) dosing schedule.
Although it is recognised to be more convenient to be able to recommend a bid dosing schedule for paediatric formulations, to avoid having to give medicine during the middle of the day when the child may be at school, not all drug substances have pharmocokinetics which are compatible with such a regimen.
In addition, gastric intolerance, manifested in symptons such as loose stools, is perceived in some countries to be a side effect associated with the use of amoxycillin/potassium clavulanate in the present tid dosage regimes.
Accordingly, any measures, such as revised dosage regimes, which can mitigate this would be advantageous.
The present invention therefore provides a method of treating bacterial infections in paediatric patients which method comprises administering to a patient in need thereof, preferably as a liquid aqueous suspension, amoxycillin trihydrate and potassium clavulanate in combination, in a weight ratio of between 6:1 and 8:1, preferably about 6.5:1 to 7.5:1, more preferably about 7:1 (the weights being expressed as the free parent acids amoxycillin and clavulanic acid), such administration being twice daily (bid) and at a dosage of between 15 and 80mg/kg/day, preferably 20 and 75mg/kg/day, more preferably 20 and 70mg/kg/day, suitably 40 and 70mg/kg/day, of amoxycillin and pro rata amounts of clavulanic acid.
The term 'paediatric' as used herein means children in the age range from 0 to about 12 years.
The method is suitable for all infections for which the combination of amoxycillin trihydrate and potassium clavulanate is normally prescribed, for instance infections of the upper and lower respiratory tract, urinary tract, skin and skin structures, for example otitis media.
Suitabably the twice daily (bid) administration is at 12 hour intervals, although a greater or lesser interval between administrations may be used.
Representative daily amounts of amoxycillin/potassium clavulanate include 25/3.6, 35/5, 45/6.4 and 70/10~10%mg/kg/day.
In a further aspect, the present invention provides for pharmaceutical compositions for use in the aforementioned method of treatment, these compositions being distinguishable over previously available compositions on account of the different ratio of amoxycillin trihydrate:potassium clavulanate used and the differing amounts of amoxycillin trihydrate and potassium clavulanate per unit dose, to achieve the higher daily dosage regime.
The invention therefore provides a pharmaceutical formulation suitable for paediatric oral bid administration, comprising amoxycillin trihydrate and potassium clavulanate in combination, in a weight ratio of between 6:1 and 8:1, preferably about 6.5:1 to 7.5:1, more preferably about 7:1 (the weights being expressed as the free parent acids amoxycillin and clavulanic acid), and in quantities such as to provide between between 15 and 80mg/kg/day, preferably 20 and 75mg/kg/day, more R'O 96/346ID5 PCT/EP96/01881 preferably 20 and 70mg/kg/day, suitably 40 and 7Umg/kg/day, of amoxyciitlin and pro rata amounts of clavulanic acid.
Formulations according to the present invention are preferably provided in the form of a dry powder or granule formulation for reconstitution into an aqueous S suspension with water or other suitable aqueous media, shortly before administration.
'lChe present invention covers such dry powder and granule formulations as well as liquid aqueous preparations.
Such dry formulations may be provided in a substantially air-tight c:on,tainer such as a bottle or sachet, and this container may suitably include a desiccant to F~rotect the potassium clavulanate from degradation by atmospheric water vapour.
Potassium clavulanate is highly moisture sensitive, and the formulations of this invention should be made under conditions of relative humidty (RH) as lour as possible, preferably 30% RH or less.
The formulation of this invention is provided for bid administration, which ideally may comprise two administrations at 12 hour dosage intervals, although a greater or lesser interval between administrations may be used.
Suitably, formulations according to the present invention are provided in amounts such that the liquid aqueous suspension contains in a convenient volume, typically within the range 2 to IOmI, preferably about Sml, of suspension, a~
unit dosage of amoxycillin and potassium clavulanate. The volume may be measured by any conventional measuring device such as a spoon, syringe or graduated measuring cup. Unit dosages typically lie within the range 50 to 800mg of amoxycillin plus pro rata amounts of potassium clavulanate. It will be appreciated that the appropriate unit dosage will be at the discretion of the physician and will depend inter alia upon tile age and weight of the patient and the nature and severity of the infection to be ~-ea.ted.
It is found to be convenient to provide paediatric formulations in a lower (for mild-moderate infections) and a higher strength (for severe infections). The suitable formulations, when made up as aqueous liquid suspensions, will contain from 100 to 400mg, or 200 to 800mg amoxycillin per Sml of suspension plus pro rata amounts of potassium clavulanate. Representative examples include:
amoxycillin potassium clavulanate 200 28.515m1 suspension 400 57;
v~rithin a tolerance of ~10%. .
Accordingly, in a further aspect, the present. invention provides a pharmaceutical formulation adapted for reconstitution as a liquid aqueous suspension comprising amoxycillin trihydrate and potassium clavulanate and which, when rE:consituted, comprises amoxycillin in an amount 200~10% and clavulanic acid in an
For children, it is preferred to provide the combination as a powder which is reconstituted prior to use as a liquid aqueous suspension. The usual recommended daily dosage is 20/Smg/kg/day (LTK and USA) or 3017.5mg/kg/day (Continental >=;urope) amoxycillin/potassium clavulanate (ratio 4:1), in divided doses every eight hours. For more severe infections such as otitis media, sinusitis and lower mspiraotory tract infections, the recommended dose is 40/lOmg/kg/day (UK and LJSA) or 60/lSmg/kg/day (Continental Europe), in three divided doses. For convenience, the powders are provided in amounts which are made up into a range of volumes of suspension so that a small volume, typically about Sml, contains a unit dosage. In other countries such as Italy, approval has also been given for using the higher strength paediatric formulation on a twice a day (bid) dosing schedule.
Although it is recognised to be more convenient to be able to recommend a bid dosing schedule for paediatric formulations, to avoid having to give medicine during the middle of the day when the child may be at school, not all drug substances have pharmocokinetics which are compatible with such a regimen.
In addition, gastric intolerance, manifested in symptons such as loose stools, is perceived in some countries to be a side effect associated with the use of amoxycillin/potassium clavulanate in the present tid dosage regimes.
Accordingly, any measures, such as revised dosage regimes, which can mitigate this would be advantageous.
The present invention therefore provides a method of treating bacterial infections in paediatric patients which method comprises administering to a patient in need thereof, preferably as a liquid aqueous suspension, amoxycillin trihydrate and potassium clavulanate in combination, in a weight ratio of between 6:1 and 8:1, preferably about 6.5:1 to 7.5:1, more preferably about 7:1 (the weights being expressed as the free parent acids amoxycillin and clavulanic acid), such administration being twice daily (bid) and at a dosage of between 15 and 80mg/kg/day, preferably 20 and 75mg/kg/day, more preferably 20 and 70mg/kg/day, suitably 40 and 70mg/kg/day, of amoxycillin and pro rata amounts of clavulanic acid.
The term 'paediatric' as used herein means children in the age range from 0 to about 12 years.
The method is suitable for all infections for which the combination of amoxycillin trihydrate and potassium clavulanate is normally prescribed, for instance infections of the upper and lower respiratory tract, urinary tract, skin and skin structures, for example otitis media.
Suitabably the twice daily (bid) administration is at 12 hour intervals, although a greater or lesser interval between administrations may be used.
Representative daily amounts of amoxycillin/potassium clavulanate include 25/3.6, 35/5, 45/6.4 and 70/10~10%mg/kg/day.
In a further aspect, the present invention provides for pharmaceutical compositions for use in the aforementioned method of treatment, these compositions being distinguishable over previously available compositions on account of the different ratio of amoxycillin trihydrate:potassium clavulanate used and the differing amounts of amoxycillin trihydrate and potassium clavulanate per unit dose, to achieve the higher daily dosage regime.
The invention therefore provides a pharmaceutical formulation suitable for paediatric oral bid administration, comprising amoxycillin trihydrate and potassium clavulanate in combination, in a weight ratio of between 6:1 and 8:1, preferably about 6.5:1 to 7.5:1, more preferably about 7:1 (the weights being expressed as the free parent acids amoxycillin and clavulanic acid), and in quantities such as to provide between between 15 and 80mg/kg/day, preferably 20 and 75mg/kg/day, more R'O 96/346ID5 PCT/EP96/01881 preferably 20 and 70mg/kg/day, suitably 40 and 7Umg/kg/day, of amoxyciitlin and pro rata amounts of clavulanic acid.
Formulations according to the present invention are preferably provided in the form of a dry powder or granule formulation for reconstitution into an aqueous S suspension with water or other suitable aqueous media, shortly before administration.
'lChe present invention covers such dry powder and granule formulations as well as liquid aqueous preparations.
Such dry formulations may be provided in a substantially air-tight c:on,tainer such as a bottle or sachet, and this container may suitably include a desiccant to F~rotect the potassium clavulanate from degradation by atmospheric water vapour.
Potassium clavulanate is highly moisture sensitive, and the formulations of this invention should be made under conditions of relative humidty (RH) as lour as possible, preferably 30% RH or less.
The formulation of this invention is provided for bid administration, which ideally may comprise two administrations at 12 hour dosage intervals, although a greater or lesser interval between administrations may be used.
Suitably, formulations according to the present invention are provided in amounts such that the liquid aqueous suspension contains in a convenient volume, typically within the range 2 to IOmI, preferably about Sml, of suspension, a~
unit dosage of amoxycillin and potassium clavulanate. The volume may be measured by any conventional measuring device such as a spoon, syringe or graduated measuring cup. Unit dosages typically lie within the range 50 to 800mg of amoxycillin plus pro rata amounts of potassium clavulanate. It will be appreciated that the appropriate unit dosage will be at the discretion of the physician and will depend inter alia upon tile age and weight of the patient and the nature and severity of the infection to be ~-ea.ted.
It is found to be convenient to provide paediatric formulations in a lower (for mild-moderate infections) and a higher strength (for severe infections). The suitable formulations, when made up as aqueous liquid suspensions, will contain from 100 to 400mg, or 200 to 800mg amoxycillin per Sml of suspension plus pro rata amounts of potassium clavulanate. Representative examples include:
amoxycillin potassium clavulanate 200 28.515m1 suspension 400 57;
v~rithin a tolerance of ~10%. .
Accordingly, in a further aspect, the present. invention provides a pharmaceutical formulation adapted for reconstitution as a liquid aqueous suspension comprising amoxycillin trihydrate and potassium clavulanate and which, when rE:consituted, comprises amoxycillin in an amount 200~10% and clavulanic acid in an
-3-amount 28.5'10% or amoxycillin in an amount 400~10% and clavulanic acid in an amount 57~10% mg/Sml of liquid aqueous suspension.
In a representative example, for a unit dosages of Sml, the suspension is made up to a total volume of 100m1. It will however be appreciated that a range of total volumes may be used, to adjust the amount in a unit dose to an amount appropriate for the individual patient. It will be appreciated that it may also be convenient to provide a higher strength formulation to a patient with a larger body weight, so that the unit volume is kept reasonable.
The formulation of this invention will normally comprise, in addition to its active materials amoxycillin trihydrate and potassium clavulanate, excipients which are standard in the field of paediatric pharmaceutical oral suspensions. These will be used in generally standard proportions, and at generally standard particle sizes and grades etc.. Such excipients may comprise suspending aids, glidants (to aid filling), diluents, bulking agent, flavours, sweeteners, stabilisers, and, in the case of dry formulations for make-up to an aqueous suspension, an edible desiccant to assist preservation of the potassium clavulanate against hydrolysis by atmospheric moisture on storage. Potassium clavulanate is normally supplied in admixture with silicon dioxide as diluent. Suitable excipients for use include xanthan gum (suspension aid), colloidal silica (glidant), succinic acid (stabiliser), aspartame (sweetener), hydroxypropylmethylcellulose (suspension aid) and silicon dioxide (desiccant, diluent for potassium clavulanate and bulking agent. Flavours may comprise common flavours such as orange, banana, raspberry and golden syrup, or mixtures thereof, to suit local requirements.
Mannitol is often used in pharmaceutical formulations as an excipient. It is however recognised to have, at least at certain levels, a diuretic effect. It has found to be advantageous to avoid the use of excessive amounts of mannitol in formulations comprising amoxycillin/potassium clavulanate, as it is thought that this may be associated with reduced levels of gastric irntancy. Accordingly, the present invention provides for a pharmaceutical formulation as hereinbefore defined and which is substantially mannitol-free.
Generally the proportion of active materials amoxycillin trihydrate and potassium clavulanate in a dry formulation for make-up with aqueous media into a suspension formulation of the invention may be around 35-60, e.g. 35-50 wt%.
The formulation of the invention may be manufactured using techniques which are generally conventional in the field of manufacture of paediatric suspension formulations and manufacture of dry formulations for reconstitution into such suspensions. For example a suitable technique is that of mixing dry powdered or granulated ingredients for loading into a suitable container.
In a representative example, for a unit dosages of Sml, the suspension is made up to a total volume of 100m1. It will however be appreciated that a range of total volumes may be used, to adjust the amount in a unit dose to an amount appropriate for the individual patient. It will be appreciated that it may also be convenient to provide a higher strength formulation to a patient with a larger body weight, so that the unit volume is kept reasonable.
The formulation of this invention will normally comprise, in addition to its active materials amoxycillin trihydrate and potassium clavulanate, excipients which are standard in the field of paediatric pharmaceutical oral suspensions. These will be used in generally standard proportions, and at generally standard particle sizes and grades etc.. Such excipients may comprise suspending aids, glidants (to aid filling), diluents, bulking agent, flavours, sweeteners, stabilisers, and, in the case of dry formulations for make-up to an aqueous suspension, an edible desiccant to assist preservation of the potassium clavulanate against hydrolysis by atmospheric moisture on storage. Potassium clavulanate is normally supplied in admixture with silicon dioxide as diluent. Suitable excipients for use include xanthan gum (suspension aid), colloidal silica (glidant), succinic acid (stabiliser), aspartame (sweetener), hydroxypropylmethylcellulose (suspension aid) and silicon dioxide (desiccant, diluent for potassium clavulanate and bulking agent. Flavours may comprise common flavours such as orange, banana, raspberry and golden syrup, or mixtures thereof, to suit local requirements.
Mannitol is often used in pharmaceutical formulations as an excipient. It is however recognised to have, at least at certain levels, a diuretic effect. It has found to be advantageous to avoid the use of excessive amounts of mannitol in formulations comprising amoxycillin/potassium clavulanate, as it is thought that this may be associated with reduced levels of gastric irntancy. Accordingly, the present invention provides for a pharmaceutical formulation as hereinbefore defined and which is substantially mannitol-free.
Generally the proportion of active materials amoxycillin trihydrate and potassium clavulanate in a dry formulation for make-up with aqueous media into a suspension formulation of the invention may be around 35-60, e.g. 35-50 wt%.
The formulation of the invention may be manufactured using techniques which are generally conventional in the field of manufacture of paediatric suspension formulations and manufacture of dry formulations for reconstitution into such suspensions. For example a suitable technique is that of mixing dry powdered or granulated ingredients for loading into a suitable container.
-4-
5 PCT/EP96/01881 The present invention therefore provides a process for manufacture of a formulation as described above.
The invention also provides for the use of amoxycillin trihydrate and potassium clavulanate as described above in the manufacture of a medicament which is provided for paediatric oral BID administration for use in the treatment of bacterial ' infections.
The invention will now be described by way of non-limiting example only.
E:~ample 1 Two formulations of this invention having a composition as listed below were prepared using conventional techniques as dry powder mixtures. The proportions of ingredients are expressed as mg/Sml dose of reconstituted aqueous suspension:
Ingredient mg/Sml mg/Sml annoxycillin trihydrate*408.0 204.0 potassium clavulanate*61.56 30.78 xaalthan gum 12.5 12.5 colloidal silica 25.0 25.0 succinnic acid 0.84 '0.84 orange flavour 26.25 26.25 golden syrup flavour 23.75 23.75 aspartame 12.50 12.50 h5~droxypropylmethylcellulose79.65 79.65 silicon dioxide to 885.5 to 537.5 * expressed as free acid equivalent.
The above two formulations were manufactured in 100 kg batches.
Cliinical Trial - A
In a multicentre randomized trial, the safety and efficacy in the treatment of aicute Oaitis Media in children of formulations according to the present invention and comprising amoxycillin/potassium clavulanate in a ratio of 7: l, at a level of 4E5/6.4 mg/kg/day (ratio 7:1) and in divided doses ql2h (BID) were compared with au currently approved US formulation comprising amo~;ycillin/potassium clavulanate in a lratio 4:1 administered at a level of 40/lOmg/kg/day amoxycillin/potassium cl;avulanate acid in divided doses q 8h (TID). 287 children received the BID
rel;imen for 10 days and 288 children received the TID regimen for 10 days. The forrnulations according to the present invention were mannitol-free whilst the currently approved US formulation contained mannitol.
The BID regimen was shown to be as safe as the TID regimen. Standard diary cards were used to assess the incidence of incidence of protocol-defined diarrhoea (i.e. 3 or more watery stools in one day, or 2 watery stools per day for two consecutive days.
This was found to be significantly lower for the BID regimen (7.9%) when compared with the TID regimen (22.2%) [95% CI: (-20.5%, -8.1%) ]. Similar trends were observed for withdrawals due to diarrhoea (2.8% and 7.6% respectively; p =
0.009), confirming improved patient tolerance compared with the current regimen.
The per protocol clinical success rates at the end of therapy (days 12 to 14) were equivalent for the BID regimen (86.5%) and the TID regimen (78.88%). Similar trends in efficacy were noted at follow-up (days 32 to 38).
Formulations used Ingredient bid bid tid tid mg/Sml mg/5ml mg/Sml mg/Sml amoxycillin trihydrate*408.0 204.0 130.00 260.00 potassium clavulanate*61.56 30.78 35.00 70.00 xanthan gum 12.5 12.5 15.00 15.00 sodium saccharin 4.00 4.00 colloidal silica 25.0 25.0 25.00 25.00 succinnic acid 0.84 0.84 0.85 0.85 banana flavour 20.00 orange flavour 26.25 26.25 23.00 golden syrup flavour 23.75 23.75 aspartame 12.50 12.50 hydroxypropylmethylcellulose79.65 79.65 silicon dioxide to 885.5 to 537.5 82.30 39.70 mannitol to 900.00to 1200.00 * expressed as free acid equivalent.
Clinical trial - B
In a multicentre randomized trial, the safety and efficacy in the treatment of acute Otitis Media in children of formulations according to the present invention and
The invention also provides for the use of amoxycillin trihydrate and potassium clavulanate as described above in the manufacture of a medicament which is provided for paediatric oral BID administration for use in the treatment of bacterial ' infections.
The invention will now be described by way of non-limiting example only.
E:~ample 1 Two formulations of this invention having a composition as listed below were prepared using conventional techniques as dry powder mixtures. The proportions of ingredients are expressed as mg/Sml dose of reconstituted aqueous suspension:
Ingredient mg/Sml mg/Sml annoxycillin trihydrate*408.0 204.0 potassium clavulanate*61.56 30.78 xaalthan gum 12.5 12.5 colloidal silica 25.0 25.0 succinnic acid 0.84 '0.84 orange flavour 26.25 26.25 golden syrup flavour 23.75 23.75 aspartame 12.50 12.50 h5~droxypropylmethylcellulose79.65 79.65 silicon dioxide to 885.5 to 537.5 * expressed as free acid equivalent.
The above two formulations were manufactured in 100 kg batches.
Cliinical Trial - A
In a multicentre randomized trial, the safety and efficacy in the treatment of aicute Oaitis Media in children of formulations according to the present invention and comprising amoxycillin/potassium clavulanate in a ratio of 7: l, at a level of 4E5/6.4 mg/kg/day (ratio 7:1) and in divided doses ql2h (BID) were compared with au currently approved US formulation comprising amo~;ycillin/potassium clavulanate in a lratio 4:1 administered at a level of 40/lOmg/kg/day amoxycillin/potassium cl;avulanate acid in divided doses q 8h (TID). 287 children received the BID
rel;imen for 10 days and 288 children received the TID regimen for 10 days. The forrnulations according to the present invention were mannitol-free whilst the currently approved US formulation contained mannitol.
The BID regimen was shown to be as safe as the TID regimen. Standard diary cards were used to assess the incidence of incidence of protocol-defined diarrhoea (i.e. 3 or more watery stools in one day, or 2 watery stools per day for two consecutive days.
This was found to be significantly lower for the BID regimen (7.9%) when compared with the TID regimen (22.2%) [95% CI: (-20.5%, -8.1%) ]. Similar trends were observed for withdrawals due to diarrhoea (2.8% and 7.6% respectively; p =
0.009), confirming improved patient tolerance compared with the current regimen.
The per protocol clinical success rates at the end of therapy (days 12 to 14) were equivalent for the BID regimen (86.5%) and the TID regimen (78.88%). Similar trends in efficacy were noted at follow-up (days 32 to 38).
Formulations used Ingredient bid bid tid tid mg/Sml mg/5ml mg/Sml mg/Sml amoxycillin trihydrate*408.0 204.0 130.00 260.00 potassium clavulanate*61.56 30.78 35.00 70.00 xanthan gum 12.5 12.5 15.00 15.00 sodium saccharin 4.00 4.00 colloidal silica 25.0 25.0 25.00 25.00 succinnic acid 0.84 0.84 0.85 0.85 banana flavour 20.00 orange flavour 26.25 26.25 23.00 golden syrup flavour 23.75 23.75 aspartame 12.50 12.50 hydroxypropylmethylcellulose79.65 79.65 silicon dioxide to 885.5 to 537.5 82.30 39.70 mannitol to 900.00to 1200.00 * expressed as free acid equivalent.
Clinical trial - B
In a multicentre randomized trial, the safety and efficacy in the treatment of acute Otitis Media in children of formulations according to the present invention and
-6-WO 96/34b05 PCTIEP96/01881 comprising amoxycillin/potassium clavulanate in a ratio of 7:1, at a level of
7~D/lOmglkg/day (ratio 7:1) and in two divided doses (BID) were compared with a ci.~iTently approved European formulation comprising amoxycillin/potassium~
cl:av~ulanate in a ratio 4:1 administered at a level of 60/lSmg/kg/day vnoxycillin/potassium clavulanate acid in three divided doses ('ITD).
Childt~en aged from 2-12 years were randomised to 10 days treatment, with 231 children receiving tt~e BID regimen and 232 children receiving the TID regimen.
The BID regimen was shown to be as safe as the TID regimen. Standard diary cards were used to assess the incidence of protocol-defined diarrhoea (i.e. 3 or more watery stools in one day, or 2 watery stools per day for two consecutive days). The overall incidence was found to be low, with a lower incidence in the BID group (6.T%) than in the TID group (10.3%) although this was not statistically significant [difff;rence -3.6%; 95% CI (-8.72%, 1.58%)].
Clinical success rates at the end of therapy were 91.8% for the BID regimen and 9~D.5% for the T'ID regimen [difference 1.3%,: 95% CI (-3.92%, 6.43%)] and at follow-up were 80.1% for the BID group and 77.6% for the TID group [difference 2..5%; 95% CI (-4.94%, 9.94%)].
More patients in the BID group (81.3%) than in the TID group (72.8%) had at least
cl:av~ulanate in a ratio 4:1 administered at a level of 60/lSmg/kg/day vnoxycillin/potassium clavulanate acid in three divided doses ('ITD).
Childt~en aged from 2-12 years were randomised to 10 days treatment, with 231 children receiving tt~e BID regimen and 232 children receiving the TID regimen.
The BID regimen was shown to be as safe as the TID regimen. Standard diary cards were used to assess the incidence of protocol-defined diarrhoea (i.e. 3 or more watery stools in one day, or 2 watery stools per day for two consecutive days). The overall incidence was found to be low, with a lower incidence in the BID group (6.T%) than in the TID group (10.3%) although this was not statistically significant [difff;rence -3.6%; 95% CI (-8.72%, 1.58%)].
Clinical success rates at the end of therapy were 91.8% for the BID regimen and 9~D.5% for the T'ID regimen [difference 1.3%,: 95% CI (-3.92%, 6.43%)] and at follow-up were 80.1% for the BID group and 77.6% for the TID group [difference 2..5%; 95% CI (-4.94%, 9.94%)].
More patients in the BID group (81.3%) than in the TID group (72.8%) had at least
8~0% compliance over a 7-10 day treatment period [difference 10.3%; 95% C:I
(:?.78%, 17.76%)].
_7_ Formulations used Ingredient bid formulationtid formulation mg/Sml mg/Sml amoxycillin trihydrate*400.0 250.00 x potassium clavulanate*59.85 65.63 xanthan gum 12.50 12.50 colloidal silica 25.00 25.00 succinnic acid 0.84 0.84 orange flavour 26.25 26.25 raspberry flavour 22.50 golden syrup flavour 23.75 23.75 aspartame 12.50 12.50 hydroxypropylmethylcellulose79.65 150.00 silicon dioxide to 885.5 125.00 * expressed as free acid equivalent.
_g_
(:?.78%, 17.76%)].
_7_ Formulations used Ingredient bid formulationtid formulation mg/Sml mg/Sml amoxycillin trihydrate*400.0 250.00 x potassium clavulanate*59.85 65.63 xanthan gum 12.50 12.50 colloidal silica 25.00 25.00 succinnic acid 0.84 0.84 orange flavour 26.25 26.25 raspberry flavour 22.50 golden syrup flavour 23.75 23.75 aspartame 12.50 12.50 hydroxypropylmethylcellulose79.65 150.00 silicon dioxide to 885.5 125.00 * expressed as free acid equivalent.
_g_
Claims (7)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. The use of an antibacterially effective amount of a formulation comprising amoxycillin trihydrate and potassium clavulanate in combination, in a weight ratio of 7:1 (the weights being expressed as the free parent acids amoxycillin and clavulanic acid), the formulation being used twice daily (bid), at a dosage of between 20 and 70mg/kg/day of amoxycillin and pro rata amounts of clavulanic acid, for treating bacterial infections in paediatric patients.
2. A use as claimed in claim 1 in which the dosage regimen is 70 mg/kg/day amoxycillin in combination with 10 mg/kg/day clavulanic acid.
3. A use as claimed in claim 1 in which the dosage regimen is 45 mg/kg/day amoxycillin in combination with 6.4 mg/kg/day clavulanic acid.
4. A use as claimed in claim 1 in which the dosage regimen is 35 mg/kg/day amoxycillin in combination with 5 mg/kg/day clavulanic acid.
5. A pharmaceutical formulation adapted for paediatric oral bid administration, comprising amoxycillin tryhydrate and potassium clavulanate in combination, in a weight ratio of 7:1 (the weights being expressed as the free parent acids amoxycillin and clavulanic acid) and which, when reconsituted, comprises amoxycillin in an amount of from 150 to 450mg/5ml of liquid aqueous suspension and clavulanic acid in an amount of from 25 to 75mg/5ml of liquid aqueous suspension.
6. A formulation as claimed in claim 5 which is substantially free of a mannitol.
7. A formulation as claimed in claim 5 having a composition with ~ 10% of the formulae listed below, expressed as mg/5ml dose of reconstituted aqueous suspension:
Ingredient mg/5ml mg/5ml amoxycillin trihydrate 408.0 204.0 potassium clavulanate 61.56 30.78 xanthan gum 12.5 12.5 colloidal silica 25.0 25.0 succinnic acid 0.84 0.84 orange flavour 15.0 15.0 orange flavour 11.25 11.25 golden syrup flavour 23.75 23.75 aspartame 12.5 12.5 hydroxypropylmethycellulose 79.65 79.65 silicon dioxide to 885.5 to 537.5.
Ingredient mg/5ml mg/5ml amoxycillin trihydrate 408.0 204.0 potassium clavulanate 61.56 30.78 xanthan gum 12.5 12.5 colloidal silica 25.0 25.0 succinnic acid 0.84 0.84 orange flavour 15.0 15.0 orange flavour 11.25 11.25 golden syrup flavour 23.75 23.75 aspartame 12.5 12.5 hydroxypropylmethycellulose 79.65 79.65 silicon dioxide to 885.5 to 537.5.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9508989.2 | 1995-05-03 | ||
| GBGB9508989.2A GB9508989D0 (en) | 1995-05-03 | 1995-05-03 | Pharmaceutical formulations |
| GBGB9523655.0A GB9523655D0 (en) | 1995-11-18 | 1995-11-18 | Method of treatment |
| GB9523655.0 | 1995-11-18 | ||
| PCT/EP1996/001881 WO1996034605A1 (en) | 1995-05-03 | 1996-05-02 | Composition comprising amoxycillin and clavulanic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2220103A1 CA2220103A1 (en) | 1996-11-07 |
| CA2220103C true CA2220103C (en) | 2006-06-20 |
Family
ID=37392932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002220103A Expired - Lifetime CA2220103C (en) | 1995-05-03 | 1996-05-02 | Composition comprising amoxycillin and clavulanic acid |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2220103C (en) |
-
1996
- 1996-05-02 CA CA002220103A patent/CA2220103C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2220103A1 (en) | 1996-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU712269C (en) | Composition comprising amoxycillin and clavulanic acid | |
| AU722657B2 (en) | Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia | |
| EP0862431B1 (en) | Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate | |
| US20020099044A1 (en) | Composition comprising amoxycillin and clavulanic acid | |
| ZA200510098B (en) | Pharmaceutical formulations comprising amoxicillin and clavulanate | |
| CA2220103C (en) | Composition comprising amoxycillin and clavulanic acid | |
| EP1491195A1 (en) | Pharmaceutical formulations comprising amoxicillin and clavulanate | |
| MXPA99001807A (en) | Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant streptococcus pneumonia | |
| CZ11407U1 (en) | A pharmaceutical composition adapted for pediatric administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160502 |